id,sentences,label,sentences_tokens,cuis
0,"10 |||  ||| 0.10 ||| There was no significant difference between the groups with respect to the number of women who delivered within 24 hours or who required oxytocin augmentation of labour, the mode of delivery, and neonatal outcomes (P > 0 .05).",N,difference respect women delivered 24 hours required oxytocin augmentation labour mode delivery neonatal outcomes 0 05,C1705241|C0679133|C0043210|C1705822|C0450371|C0439227|C1514873|C0030095|C1293122|C0022864|C1513371|C0011209|C1552240|C1274040|G0000000|C0450371
1,7 |||  ||| 0.7 ||| Résumé Objectifs : Évaluer et comparer l'efficacité et l'innocuité de 50 µg de misoprostol par voie orale et de 25 µg de misoprostol par voie intravaginale pour le déclenchement du travail à terme.,N,rsum objectifs valuer comparer lefficacit linnocuit de 50 de misoprostol par voie orale de 25 de misoprostol par voie intravaginale pour le dclenchement du travail terme,G0000000|G0000000|C0401806|G0000000|G0000000|G0000000|C0011198|C0450371|C0011198|C0085174|C1417826|G0000000|C2333746|C0011198|C0450371|C0011198|C0085174|C1417826|G0000000|G0000000|G0000000|C0023190|G0000000|C0011535|G0000000|G0000000
2,"61 ||| METHODS ||| 3.9 ||| Cardiotocography was instituted before induction, and was repeated before each insertion of misoprostol and then intermittently during labour.",N,cardiotocography instituted induction repeated insertion misoprostol intermittently labour,C0007208|C0021622|C0205263|C0205341|C0021107|C0085174|G0000000|C0022864
3,6 |||  ||| 0.6 ||| Time to delivery and outcome data for each group were compared.,O,time delivery outcome data compared,C0040223|C0011209|C1274040|C1511726|C1707455
4,"36 |||  ||| 0.36 ||| Conclusion : Le misoprostol administré par voie orale à raison  de 50 µg toutes les quatre heures, jusqu'à un maximum de  cinq doses, présente le potentiel de déclencher le travail de façon  tout aussi sûre et efficace que le misoprostol administré par voie  vaginale à raison de 25 µg toutes les quatre heures .",O,conclusion le misoprostol administr par voie orale raison de 50 toutes les quatre heures jusqu maximum de cinq doses prsente le potentiel de dclencher le travail de faon tout aussi sre efficace le misoprostol administr par voie vaginale raison de 25 toutes les quatre heures,C1707478|C0023190|C0085174|G0000000|C1417826|G0000000|C2333746|G0000000|C0011198|C0450371|G0000000|C0227192|G0000000|G0000000|G0000000|C0806909|C0011198|G0000000|C0178602|G0000000|C0023190|G0000000|C0011198|G0000000|C0023190|G0000000|C0011198|G0000000|G0000000|G0000000|G0000000|G0000000|C0023190|C0085174|G0000000|C1417826|G0000000|G0000000|G0000000|C0011198|C0450371|G0000000|C0227192|G0000000|G0000000
5,145 ||| ACKNOWLEDGEMENTS ||| 6.8 ||| Other authors have also reported more frequent occurrence of uterine hyperstimulation syndrome and a higher intervention rate for fetal distress in women receiving vaginal misoprostol.,O,authors reported frequent occurrence uterine hyperstimulation syndrome intervention rate fetal distress women receiving vaginal misoprostol,C3812881|C0684224|C0332183|C0243132|C0042149|G0000000|C0039082|C0886296|C0871208|C0015965|C0231303|C0043210|C1514756|C0042232|C0085174
6,"16 |||  ||| 0.16 ||| Résultats : Huit (3,5 %) de ces 228 femmes ont été exclues de l'analyse puisqu'elles ont révoqué leur consentement à la suite de la randomisation.",N,rsultats huit 3 5 % de ces 228 femmes ont exclues de lanalyse puisquelles ont rvoqu leur consentement la suite de la randomisation,G0000000|G0000000|G0000000|G0000000|G0000000|C0011198|C0265493|C1442061|G0000000|G0000000|G0000000|C0011198|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|C0023031|C1553446|C0011198|C0023031|C0034656
7,116 ||| DISCUSSION ||| 5.3 ||| Similar observations were made by Paungmora et al.,N,observations paungmora al,C0302523|G0000000|C0202311
8,34 |||  ||| 0.34 ||| Comparative Evaluation of 50 Microgram Oral Misoprostol and 25 Microgram Intravaginal Misoprostol for Induction of Labour at Term,N,comparative evaluation 50 microgram oral misoprostol 25 microgram intravaginal misoprostol induction labour term,G0000000|C0220825|C0450371|C0439211|C0442027|C0085174|C0450371|C0439211|C0442122|C0085174|C0205263|C0022864|C0233324
9,12 |||  ||| 0.12 ||| Méthodes : Cet essai clinique randomisé n'ayant pas été mené à l'insu portait sur 228 femmes enceintes à terme qui présentaient des indications obstétricales ou médicales en ce qui concerne le déclenchement du travail.,N,mthodes cet essai clinique randomis nayant pas linsu portait sur 228 femmes enceintes terme qui prsentaient des indications obsttricales ou mdicales en ce qui concerne le dclenchement du travail,G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|C0030125|G0000000|G0000000|C0038880|C1442061|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|C0392360|G0000000|C0229118|G0000000|C0014908|C0038088|G0000000|G0000000|C0023190|G0000000|C0011535|G0000000
10,"60 ||| METHODS ||| 3.8 ||| Women in the study were monitored for uterine contractions, uterine hyperstimulation, nausea, vomiting, diarrhea, fever, and vaginal bleeding, and the progress of labour was recorded using a partogram.",P,women study monitored uterine contractions uterine hyperstimulation nausea vomiting diarrhea fever vaginal bleeding progress labour recorded partogram,C0043210|C0557651|C0030695|C0042149|C1140999|C0042149|G0000000|C0027497|C0042963|C0011991|C0015967|C0042232|C0019080|C1272688|C0022864|C0034869|G0000000
11,115 ||| DISCUSSION ||| 5.2 ||| Vaginal misoprostol has been shown to be more effective than vaginal and intracervical PGE 2 in terms of shorter induction-to-delivery interval and less need for oxytocin.,O,vaginal misoprostol effective vaginal intracervical pge 2 terms shorter induction-to-delivery interval oxytocin,C0042232|C0085174|C1280519|C0042232|C0444978|C0033559|G0000000|C0233324|C1282927|C0205263|C1272706|C0030095
12,57 ||| METHODS ||| 3.5 ||| We included women admitted through the emergency or outpatient department with an indication for induction of labour at term.,P,included women admitted emergency outpatient department indication induction labour term,C0332257|C0043210|C0184666|C0013956|C0029921|C1704729|C0392360|C0205263|C0022864|C0233324
13,"66 ||| METHODS ||| 3.14 ||| If a woman failed to establish labour or the cervix was not favourable enough to permit artificial rupture of the membranes after five doses of misoprostol, she was categorized as having a failed induction.",I,woman failed establish labour cervix favourable permit artificial rupture membranes doses misoprostol categorized failed induction,C0043210|C0231175|C0443211|C0022864|C0007874|C3640814|C0023636|C2004457|C1881712|C0025255|C0178602|C0085174|C0871968|C0231175|C0205263
14,"86 ||| METHODS ||| 3.34 ||| In cases of means and standard deviation, the two groups were compared using unpaired t test, while in cases of difference of absolute numbers chi-square tests were used.",N,standard deviation compared unpaired test difference absolute chi-square tests,C1442989|C0012727|C1707455|C2700112|C0022885|C1705241|C0205344|C1552646|C0022885
15,"64 ||| METHODS ||| 3.12 ||| Labour was established when painful uterine contractions were accompanied by ruptured membranes, a bloody ""show,"" or cervical effacement and/or dilatation.",P,labour established painful uterine contractions accompanied ruptured membranes bloody cervical effacement and/or dilatation,C0022864|C0443211|C0030193|C0042149|C1140999|G0000000|C0443294|C0025255|C0333275|C0027530|C0552443|G0000000|C0012359
16,131 ||| DISCUSSION ||| 5.18 ||| Oral misoprostol in a dose of 50 µg has the potential to induce labour as safely and effectively as 25 µg vaginally administered misoprostol.,N,oral misoprostol dose 50 potential induce labour safely effectively 25 vaginally administered misoprostol,C0442027|C0085174|C0178602|C0450371|C3245505|C0205263|C0022864|G0000000|G0000000|C0450371|G0000000|C1521801|C0085174
17,75 ||| METHODS ||| 3.23 ||| In both groups the administration of the same dose of misoprostol was repeated every four hours until regular uterine contractions were achieved or the woman had received a total of five The primary outcomes used to evaluate efficacy were the induction-to-delivery interval in women who delivered vaginally and the rate of vaginal delivery within 24 hours.,I,administration dose misoprostol repeated hours regular uterine contractions achieved woman received total primary outcomes evaluate efficacy induction-to-delivery interval women delivered vaginally rate vaginal delivery 24 hours,C0001554|C0178602|C0085174|C0205341|C0439227|C0205272|C0042149|C1140999|G0000000|C0043210|C1514756|C0439175|C0205225|C1274040|C0220825|C1280519|C0205263|C1272706|C0043210|C1705822|G0000000|C0871208|C0042232|C0011209|C0450371|C0439227
18,"82 ||| METHODS ||| 3.30 ||| Non-progression of labour was diagnosed when there was no change or minimal change in cervical dilatation in a two-hour period during the latent or the active phase of labour, or no change or minimal change in descent of the presenting part over one hour during the second stage of labour in the presence of adequate uterine contractions.",O,non-progression labour diagnosed change minimal change cervical dilatation two-hour period latent active phase labour change minimal change descent hour stage labour presence adequate uterine contractions,C3839460|C0022864|C0011900|C0392747|C0547040|C0392747|C0027530|C0012359|C0205448|C0439531|C0205275|C0205177|C0205390|C0022864|C0392747|C0547040|C0392747|C0205386|C0439227|C0205390|C0022864|C0150312|C0205410|C0042149|C1140999
19,31 |||  ||| 0.31 ||| Méthodes : Cet essai clinique randomisé n'ayant pas été mené à l'insu portait sur 228 femmes enceintes à terme qui présentaient des indications obstétricales ou médicales en ce qui concerne le déclenchement du travail .,N,mthodes cet essai clinique randomis nayant pas linsu portait sur 228 femmes enceintes terme qui prsentaient des indications obsttricales ou mdicales en ce qui concerne le dclenchement du travail,G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|C0030125|G0000000|G0000000|C0038880|C1442061|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|C0392360|G0000000|C0229118|G0000000|C0014908|C0038088|G0000000|G0000000|C0023190|G0000000|C0011535|G0000000
20,111 ||| RESULTS ||| 4.22 ||| Both of these (nulliparous) women received tocolysis and underwent urgent delivery by CS.,I,nulliparous women received tocolysis underwent urgent delivery cs,C0425979|C0043210|C1514756|C0040348|G0000000|C0439609|C0011209|C0010182
21,"30 |||  ||| 0.30 ||| Uterine hyperstimulation occurred in two women who received misoprostol vaginally, but not in any of the women in the oral misoprostol group .",I,uterine hyperstimulation occurred women received misoprostol vaginally women oral misoprostol,C0042149|G0000000|C1709305|C0043210|C1514756|C0085174|G0000000|C0043210|C0442027|C0085174
22,134 ||| DISCUSSION ||| 5.21 ||| The,N,NULL,NULL
23,"19 |||  ||| 0.19 ||| Une hyperstimulation utérine s'est manifestée chez deux des femmes 408 l MAY JOGC MAI 2013 Comparative Evaluation of 50 Microgram Oral Misoprostol and 25 Microgram Intravaginal Misoprostol for Induction of Labour at Term qui avaient reçu du misoprostol par voie vaginale; toutefois, aucune des femmes ayant reçu du misoprostol par voie orale n'a été affectée par un tel phénomène .",N,une hyperstimulation utrine sest manifeste chez deux des femmes 408 jogc mai 2013 comparative evaluation 50 microgram oral misoprostol 25 microgram intravaginal misoprostol induction labour term qui avaient reu du misoprostol par voie vaginale toutefois aucune des femmes ayant reu du misoprostol par voie orale affecte par tel phnomne,G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|C1442061|G0000000|C0026914|G0000000|G0000000|C0220825|C0450371|C0439211|C0442027|C0085174|C0450371|C0439211|C0442122|C0085174|C0205263|C0022864|C0233324|G0000000|G0000000|C0035373|C0011535|C0085174|C1417826|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|C0035373|C0011535|C0085174|C1417826|G0000000|C2333746|G0000000|C1417826|C0254343|G0000000
24,"35 |||  ||| 0.35 ||| qui avaient reçu du misoprostol par voie vaginale; toutefois, aucune des femmes ayant reçu du misoprostol par voie orale n'a été affectée par un tel phénomène .",N,qui avaient reu du misoprostol par voie vaginale toutefois aucune des femmes ayant reu du misoprostol par voie orale affecte par tel phnomne,G0000000|G0000000|C0035373|C0011535|C0085174|C1417826|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|C0035373|C0011535|C0085174|C1417826|G0000000|C2333746|G0000000|C1417826|C0254343|G0000000
25,"41 ||| INTRODUCTION ||| 1.4 ||| However, it has several disadvantages: it is expensive, it requires continuous refrigeration, and it is not widely available.",I,disadvantages expensive requires continuous refrigeration,G0000000|C0680864|G0000000|C0549178|C0034957
26,141 ||| ACKNOWLEDGEMENTS ||| 6.4 ||| The authors would like to thank Professor (Dr) B.K.,N,authors professor dr,C3812881|C0599518|C0013014
27,136 ||| DISCUSSION ||| 5.23 ||| Comparison of labour outcomes,N,comparison labour outcomes,C1707455|C0022864|C1274040
28,"71 ||| METHODS ||| 3.19 ||| Once a woman consented to participate in the trial, the next sealed envelope was opened, irreversibly randomizing her group allocation.",I,woman consented participate trial sealed envelope irreversibly randomizing allocation,C0043210|C2711213|G0000000|C0008976|C0036492|C1622204|G0000000|G0000000|C1706778
29,"144 ||| ACKNOWLEDGEMENTS ||| 6.7 ||| None of the women in the oral misoprostol group developed hyperstimulation syndrome, but two women in the vaginal misoprostol group did so.",N,women oral misoprostol developed hyperstimulation syndrome women vaginal misoprostol,C0043210|C0442027|C0085174|G0000000|G0000000|C0039082|C0043210|C0042232|C0085174
30,"65 ||| METHODS ||| 3.13 ||| In women in either study group with inadequate uterine contractions, oxytocin was used for augmentation of labour according to our departmental protocol.",O,women study inadequate uterine contractions oxytocin augmentation labour departmental protocol,C0043210|C0557651|C0205412|C0042149|C1140999|C0030095|C1293122|C0022864|C1704729|C0442711
31,"33 |||  ||| 0.33 ||| Dans chacun de ces groupes, l'administration de la même dose de misoprostol a été répétée toutes les quatre heures jusqu'à ce que des contractions utérines régulières aient",N,dans chacun de ces groupes ladministration de la mme dose de misoprostol rpte toutes les quatre heures jusqu ce des contractions utrines rgulires aient,G0000000|G0000000|C0011198|C0265493|G0000000|G0000000|C0011198|C0023031|C3887624|C0178602|C0011198|C0085174|C3826877|G0000000|C0227192|G0000000|G0000000|G0000000|C0038088|G0000000|C1140999|G0000000|G0000000|G0000000
32,"105 ||| RESULTS ||| 4.16 ||| In the vaginal misoprostol group, three babies were admitted to NICU with suspected neonatal sepsis, two with hypoglycemia, two with jaundice, one with feeding difficulties, and one having had a seizure.",P,vaginal misoprostol babies admitted nicu suspected neonatal sepsis hypoglycemia jaundice feeding difficulties seizure,C0042232|C0085174|C0021270|C0184666|C0021709|C0332147|C1552240|C0036690|C0020615|C0022346|C0204695|C1299586|C0036572
33,52 ||| INTRODUCTION ||| 1.15 ||| We chose the oral dose of 50 µg because of our experience with this dose and the experience of other investigators with oral doses up to 200 µg.,N,chose oral dose 50 experience dose experience investigators oral doses 200,C1707391|C0442027|C0178602|C0450371|C0237607|C0178602|C0237607|C0035173|C0442027|C0178602|C1442061
34,73 ||| METHODS ||| 3.21 ||| This study was not placebo controlled.,N,study placebo controlled,C0557651|C0032042|C2587213
35,118 ||| DISCUSSION ||| 5.5 ||| In both groups the majority of the women who had failed induction were nulliparous.,I,majority women failed induction nulliparous,C0680220|C0043210|C0231175|C0205263|C0425979
36,"5 |||  ||| 0.5 ||| In each group, misoprostol administration was repeated every four hours in the same dose until regular uterine contractions were established or to a maximum of five doses.",I,misoprostol administration repeated hours dose regular uterine contractions established maximum doses,C0085174|C0001554|C0205341|C0439227|C0178602|C0205272|C0042149|C1140999|C0443211|C0806909|C0178602
37,"51 ||| INTRODUCTION ||| 1.14 ||| In view of the uncertainty regarding the preferred dose and route of administration of misoprostol for induction of labour, we designed this study to assess and compare the efficacy and safety of 50 µg oral misoprostol with 25 µg intravaginal misoprostol for induction of labour at term.",P,view uncertainty preferred dose route administration misoprostol induction labour designed study assess compare efficacy safety 50 oral misoprostol 25 intravaginal misoprostol induction labour term,C0449911|C0087130|C0558295|C0178602|C0013153|C0001554|C0085174|C0205263|C0022864|C1707689|C0557651|C1516048|C1707455|C1280519|C0036043|C0450371|C0442027|C0085174|C0450371|C0442122|C0085174|C0205263|C0022864|C0233324
38,"37 |||  ||| 0.37 ||| The most common vaginal dose used has been 50 µg, inserted once or administered every four to six hours; inserting 25 µg every six hours intravaginally has been associated with the fewest side effects.",I,common vaginal dose 50 inserted administered hours inserting 25 hours intravaginally fewest effects,C0205214|C0042232|C0178602|C0450371|C0441587|C1521801|C0439227|C0441587|C0450371|C0439227|G0000000|C0205388|C1280500
39,"59 ||| METHODS ||| 3.7 ||| Women were excluded from the study if they had a malpresentation, uterine contractions, suspected cephalo-pelvic disproportion, an estimated fetal weight > 4000 g (by clinical assessment and ultrasonography), maternal age < 18 years, parity of ≥ 5, a favourable cervix (Bishop score > 6), a previous Caesarean section or uterine scar, multiple gestation, undiagnosed vaginal bleeding, fetal distress, suspected chorioamnionitis, or a contraindication to vaginal delivery or to administration of prostaglandins .",P,women excluded study malpresentation uterine contractions suspected cephalo-pelvic disproportion estimated fetal weight 4000 clinical assessment ultrasonography maternal age < 18 parity 5 favourable cervix bishop score 6 previous caesarean uterine scar multiple gestation undiagnosed vaginal bleeding fetal distress suspected chorioamnionitis contraindication vaginal delivery administration prostaglandins,C0043210|C1554077|C0557651|C0233256|C0042149|C1140999|C0332147|C0030797|C0341906|C0750572|C0015965|C0005910|G0000000|C0205210|C1261322|C0041618|C2347083|C0001779|G0000000|C0450371|C0030563|G0000000|C3640814|C0007874|C1551458|C0449820|G0000000|C0205156|C3841297|C0042149|C0241158|C0439064|C0032961|C1408353|C0042232|C0019080|C0015965|C0231303|C0332147|C0008495|C0522473|C0042232|C0011209|C0001554|C0033554
40,"53 ||| METHODS ||| 3.1 ||| We conducted a prospective, non-blinded randomized trial in the Labour and Maternity Ward, Department of Obstetrics and Gynaecology at the Central Referral Hospital, Gangtok, India from August 1, 2010, to July 31, 2011.",P,conducted prospective non-blinded randomized trial labour maternity ward department obstetrics gynaecology central referral hospital gangtok india august 1 2010 july 31 2011,C0004927|C0023981|C1518422|C0034656|C0008976|C0022864|C0681108|C1305702|C1704729|C0028773|C0018417|C0205099|C0034927|C0019994|G0000000|C0021201|C3831448|G0000000|G0000000|C3829447|C0450371|G0000000
41,"18 |||  ||| 0.18 ||| Aucune différence significative n'a été constatée entre les deux groupes en ce qui concerne le nombre de femmes ayant accouché dans les 24 heures ou ayant nécessité une accélération du travail à l'oxytocine, le mode d'accouchement et les issues néonatales (P > 0,05).",N,aucune diffrence significative constate entre les deux groupes en ce qui concerne le nombre de femmes ayant accouch dans les 24 heures ou ayant ncessit une acclration du travail loxytocine le mode daccouchement les issues nonatales 0 05,G0000000|G0000000|G0000000|G0000000|G0000000|C0227192|G0000000|G0000000|C0014908|C0038088|G0000000|G0000000|C0023190|G0000000|C0011198|G0000000|G0000000|G0000000|G0000000|C0227192|C0450371|G0000000|C0229118|G0000000|G0000000|G0000000|G0000000|C0011535|G0000000|G0000000|C0023190|C1513371|G0000000|C0227192|C0033213|G0000000|G0000000|C0450371
42,80 ||| METHODS ||| 3.28 ||| Uterine hyperstimulation syndrome was defined as uterine tachysystole or a hypertonic uterus (single contraction lasting for at least 2 minutes) with the presence of an abnormal FHR pattern prompting intervention either with subcutaneous terbutaline or urgent delivery.,I,uterine hyperstimulation syndrome defined uterine tachysystole hypertonic uterus single contraction lasting 2 minutes presence abnormal fhr pattern prompting intervention subcutaneous terbutaline urgent delivery,C0042149|G0000000|C0039082|C1704788|C0042149|C2985339|G0000000|C0042149|C0037179|C1140999|C1517741|G0000000|C0439232|C0150312|C0205161|G0000000|C0449774|C0871157|C0886296|C0443315|C0039542|C0439609|C0011209
43,"2 |||  ||| 0.2 ||| Conclusion: Oral misoprostol in a dose of 50 µg every four hours, to a maximum of five doses, has the potential to induce labour as safely and effectively as 25 µg misoprostol administered vaginally every four hours.",O,conclusion oral misoprostol dose 50 hours maximum doses potential induce labour safely effectively 25 misoprostol administered vaginally hours,C1707478|C0442027|C0085174|C0178602|C0450371|C0439227|C0806909|C0178602|C3245505|C0205263|C0022864|G0000000|G0000000|C0450371|C0085174|C1521801|G0000000|C0439227
44,"83 ||| METHODS ||| 3.31 ||| Assuming the mean induction to vaginal delivery interval with the established dinoprostone protocol to be 24 hours, with a standard deviation of 12 hours, 10,25,26 and assuming that the use of oral misoprostol would be as effective as the established protocol, The data collected were thoroughly screened and entered into Microsoft Excel spread sheets (Microsoft Corp., Redmond, WA) for analysis.",P,assuming induction vaginal delivery interval established dinoprostone protocol 24 hours standard deviation 12 hours 10 25 26 assuming oral misoprostol effective established protocol data collected screened entered microsoft excel spread sheets microsoft corp redmond wa analysis,G0000000|C0205263|C0042232|C0011209|C1272706|C0443211|C0012472|C0442711|C0450371|C0439227|C1442989|C0012727|C0450371|C0439227|C0450371|C0450371|C0450371|G0000000|C0442027|C0085174|C1280519|C0443211|C0442711|C1511726|C1516695|C0220908|C1521975|G0000000|C2740529|C0332261|C0439643|G0000000|C0683758|G0000000|C0027366|C0002778
45,138 ||| ACKNOWLEDGEMENTS ||| 6.1 ||| 20,N,20,C0450371
46,21 |||  ||| 0.21 ||| 228 pregnant women at term with obstetric or medical indications for induction of labour .,P,228 pregnant women term obstetric medical indications induction labour,C1442061|C0549206|C0043210|C0233324|C0205484|C0199168|C0392360|C0205263|C0022864
47,"14 |||  ||| 0.14 ||| Dans chacun de ces groupes, l'administration de la même dose de misoprostol a été répétée toutes les quatre heures jusqu'à ce que des contractions utérines régulières aient été établies ou jusqu'à l'administration d'un maximum de cinq doses.",N,dans chacun de ces groupes ladministration de la mme dose de misoprostol rpte toutes les quatre heures jusqu ce des contractions utrines rgulires aient tablies ou jusqu ladministration dun maximum de cinq doses,G0000000|G0000000|C0011198|C0265493|G0000000|G0000000|C0011198|C0023031|C3887624|C0178602|C0011198|C0085174|C3826877|G0000000|C0227192|G0000000|G0000000|G0000000|C0038088|G0000000|C1140999|G0000000|G0000000|G0000000|G0000000|C0229118|G0000000|G0000000|G0000000|C0806909|C0011198|G0000000|C0178602
48,139 ||| ACKNOWLEDGEMENTS ||| 6.2 ||| more oxytocin augmentation was required in women using oral misoprostol (50 µg) than in women using vaginal misoprostol (50 µg).,I,oxytocin augmentation required women oral misoprostol 50 women vaginal misoprostol 50,C0030095|C1293122|C1514873|C0043210|C0442027|C0085174|C0450371|C0043210|C0042232|C0085174|C0450371
49,42 ||| INTRODUCTION ||| 1.5 ||| Oral misoprostol is well tolerated when used for the management of upper gastrointestinal tract dysfunction.,N,oral misoprostol tolerated management upper gastrointestinal tract dysfunction,C0442027|C0085174|G0000000|C0001554|C1282910|C0521362|C1185740|C0031847
50,88 ||| METHODS ||| 3.36 ||| With,N,NULL,NULL
51,"20 |||  ||| 0.20 ||| Methods: This non-blinded, randomized clinical trial included",I,methods non-blinded randomized clinical trial included,C0025663|C1518422|C0034656|C0205210|C0008976|C0332257
52,"67 ||| METHODS ||| 3.15 ||| The woman was then offered a different method of labour induction (e.g., with use of PGE 2 vaginal gel) after a rest period.",I,woman offered method labour induction pge 2 vaginal gel rest period,C0043210|C1444648|C0025663|C0022864|C0205263|C0033559|G0000000|C0042232|C0017243|C0035253|C0439531
53,127 ||| DISCUSSION ||| 5.14 ||| We acknowledge the likelihood that both staff and patients preferred use of oral misoprostol to vaginal misoprostol.,I,acknowledge likelihood staff patients preferred oral misoprostol vaginal misoprostol,G0000000|C0033204|C0851286|C0030705|C0558295|C0442027|C0085174|C0042232|C0085174
54,38 ||| INTRODUCTION ||| 1.1 ||| I nduction of labour is widely performed when continuation of pregnancy is hazardous to the mother or fetus.,P,nduction labour performed continuation pregnancy hazardous mother fetus,G0000000|C0022864|C0884358|G0000000|C0032961|C0598697|C0026591|C0015965
55,"47 ||| INTRODUCTION ||| 1.10 ||| However, although the efficacy was high at higher doses, there was a significantly higher incidence of abnormal uterine activity, non-reassuring fetal heart rate tracings, and meconium-stained amniotic fluid.",N,efficacy doses incidence abnormal uterine activity non-reassuring fetal heart rate tracings meconium-stained amniotic fluid,C1280519|C0178602|C0021149|C0205161|C0042149|C0205177|C1518422|C0015965|C0018787|C0871208|G0000000|C1112318|C0002630|C0005889
56,"8 |||  ||| 0.8 ||| Results: Of the 228 women, eight (3 .5%) were excluded from the analysis as they withdrew their consent after randomization.",P,228 women 3 5% excluded analysis withdrew consent randomization,C1442061|C0043210|G0000000|G0000000|C1554077|C0002778|C2349954|C1511481|C0034656
57,"142 ||| ACKNOWLEDGEMENTS ||| 6.5 ||| Kanungo (Head, Department of Obstetrics and Gynaecology, Sikkim Manipal Institute of Medical Sciences & Central Referral Hospital), Dr Golay Paden Bhutia (RMO), all the nursing staff of labour and maternity ward, and all the patients who participated in the trial, making this study possible.",I,kanungo head department obstetrics gynaecology sikkim manipal institute medical sciences central referral hospital dr golay paden bhutia rmo nursing staff labour maternity ward patients participated trial study,G0000000|C0018670|C1704729|C0028773|C0018417|C0037091|G0000000|C0021622|C0199168|C0036397|C0205099|C0034927|C0019994|C0013014|G0000000|G0000000|G0000000|G0000000|C0006147|C0851286|C0022864|C0681108|C1305702|C0030705|G0000000|C0008976|C0557651
58,"48 ||| INTRODUCTION ||| 1.11 ||| These properties make misoprostol a useful agent for induction of labour, particularly in settings in which the use of prostaglandin E 2 is not possible because of a lack of availability, a lack of facilities for storage, or financial constraints.",N,properties misoprostol agent induction labour settings prostaglandin 2 lack availability lack facilities storage financial constraints,C0871161|C0085174|C0450442|C0205263|C0022864|C0542559|C0033554|G0000000|C0332268|C0470187|C0332268|C1547538|C0337174|C0376243|C0443288
59,"120 ||| DISCUSSION ||| 5.7 ||| Labour and delivery using different doses of oral (100 µg) and vaginal (50 µg) misoprostol, although higher incidences of tachysystole and hyperstimulation syndrome were reported with these higher doses.",I,labour delivery doses oral 100 vaginal 50 misoprostol incidences tachysystole hyperstimulation syndrome reported doses,C0022864|C0011209|C0178602|C0442027|C1442061|C0042232|C0450371|C0085174|C0021149|C2985339|G0000000|C0039082|C0684224|C0178602
60,55 ||| METHODS ||| 3.3 ||| Administration of misoprostol also was stopped if there was a need for obstetric intervention.,N,administration misoprostol stopped obstetric intervention,C0001554|C0085174|C1272691|C0205484|C0886296
61,122 ||| DISCUSSION ||| 5.9 ||| The mean number of doses of misoprostol was the same in each group.,N,doses misoprostol,C0178602|C0085174
62,24 |||  ||| 0.24 ||| Time to delivery and outcome data for each group were compared .,O,time delivery outcome data compared,C0040223|C0011209|C1274040|C1511726|C1707455
63,87 ||| METHODS ||| 3.35 ||| All statistical tests were evaluated at the 0.05 significance level.,N,statistical tests evaluated 0 05 significance level,C0038215|C0022885|C0220825|G0000000|C0450371|C0237881|C0441889
64,32 |||  ||| 0.32 ||| Ces femmes ont été affectées au hasard à un groupe devant prendre 50 µg de misoprostol par voie orale (deux comprimés de 25 µg) ou à un groupe devant se faire insérer un comprimé de 25 µg de misoprostol dans le cul-de-sac postérieur du vagin .,N,ces femmes ont affectes au hasard groupe devant prendre 50 de misoprostol par voie orale deux comprims de 25 ou groupe devant se faire insrer comprim de 25 de misoprostol dans le cul-de-sac postrieur du vagin,C0265493|G0000000|G0000000|G0000000|C0004348|G0000000|G0000000|G0000000|G0000000|C0450371|C0011198|C0085174|C1417826|G0000000|C2333746|G0000000|G0000000|C0011198|C0450371|C0229118|G0000000|G0000000|C0036919|G0000000|G0000000|G0000000|C0011198|C0450371|C0011198|C0085174|G0000000|C0023190|C0013075|G0000000|C0011535|C1522570
65,129 ||| DISCUSSION ||| 5.16 ||| There is a need for a greater number of appropriately designed randomized controlled trials (preferably double-blinded) with a larger sample size to validate the efficacy and safety of 50 µg oral misoprostol in comparison with 25 µg vaginal misoprostol.,I,appropriately designed randomized controlled trials preferably double-blinded larger sample size validate efficacy safety 50 oral misoprostol comparison 25 vaginal misoprostol,G0000000|C1707689|C0034656|C2587213|C0008976|G0000000|C0205173|C0549177|C0370003|C0456389|G0000000|C1280519|C0036043|C0450371|C0442027|C0085174|C1707455|C0450371|C0042232|C0085174
66,117 ||| DISCUSSION ||| 5.4 ||| There were no differences in the modes of delivery (Table 2).,N,differences modes delivery table 2,C1705241|C1513371|C0011209|C0039224|G0000000
67,"103 ||| RESULTS ||| 4.14 ||| No significant differences between groups were found in the proportion of neonates with Apgar score < 7 at 5 minutes, the proportion delivered with meconium-stained amniotic fluid, or the proportion admitted to NICU.",N,differences proportion neonates apgar score < 7 5 minutes proportion delivered meconium-stained amniotic fluid proportion admitted nicu,C1705241|C1709707|C0021289|C0741195|C0449820|G0000000|G0000000|G0000000|C0439232|C1709707|C1705822|C1112318|C0002630|C0005889|C1709707|C0184666|C0021709
68,101 ||| RESULTS ||| 4.12 ||| Most women in each group were nulliparous (69.1% in the oral misoprostol group and 65.5% in the vaginal misoprostol group).,I,women nulliparous 69 1% oral misoprostol 65 5% vaginal misoprostol,C0043210|C0425979|C0450371|G0000000|C0442027|C0085174|C0450371|G0000000|C0042232|C0085174
69,"109 ||| RESULTS ||| 4.20 ||| Tachysystole developed in two women (1.8%) in the oral misoprostol group and six women (5.5%) in the vaginal misoprostol group (RR 0.49, 95% CI 0.15 to 1.64; P = 0.28).",I,tachysystole developed women 1 8% oral misoprostol women 5 5% vaginal misoprostol rr 0 49 95% ci 0 15 1 64 = 0 28,C2985339|G0000000|C0043210|G0000000|G0000000|C0442027|C0085174|C0043210|G0000000|G0000000|C0042232|C0085174|G0000000|G0000000|C0450371|C0450371|C0008107|G0000000|C0450371|G0000000|C0450371|G0000000|G0000000|C0450371
70,100 ||| RESULTS ||| 4.11 ||| The mean Bishop score was 3.98 in the oral misoprostol group and 4.04 in the vaginal misoprostol group.,N,bishop score 3 98 oral misoprostol 4 04 vaginal misoprostol,C1551458|C0449820|G0000000|C0450371|C0442027|C0085174|G0000000|C0450371|C0042232|C0085174
71,"104 ||| RESULTS ||| 4.15 ||| In the oral misoprostol group, two babies were admitted to NICU because of feeding problems, one because of intrauterine growth restriction, one because of suspected neonatal sepsis and one because of breathing difficulties.",I,oral misoprostol babies admitted nicu feeding intrauterine growth restriction suspected neonatal sepsis breathing difficulties,C0442027|C0085174|C0021270|C0184666|C0021709|C0204695|C0694756|C0018270|C0443288|C0332147|C1552240|C0036690|C0004048|C1299586
72,"108 ||| RESULTS ||| 4.19 ||| There were no significant differences in the occurrence of tachysystole, hypertonus, hyperstimulation syndrome and non-reassuring FHR.",N,differences occurrence tachysystole hypertonus hyperstimulation syndrome non-reassuring fhr,C1705241|C0243132|C2985339|C0026826|G0000000|C0039082|C1518422|G0000000
73,"43 ||| INTRODUCTION ||| 1.6 ||| It has excellent cervical ripening and uterotonic properties, There have been few trials assessing the efficacy and tolerability of oral misoprostol for induction of labour.",O,excellent cervical ripening uterotonic properties trials assessing efficacy tolerability oral misoprostol induction labour,C1548784|C0027530|C1160534|G0000000|C0871161|C0008976|C1516048|C1280519|C3274448|C0442027|C0085174|C0205263|C0022864
74,"132 ||| DISCUSSION ||| 5.19 ||| As oral use of the drug is easier and more convenient for both patients and caregivers, use of 50 µg oral misoprostol in this setting is preferable to the use of 25 µg vaginally inserted misoprostol.",N,oral drug easier convenient patients caregivers 50 oral misoprostol setting preferable 25 vaginally inserted misoprostol,C0442027|C0013227|C0332219|C3831015|C0030705|C0085537|C0450371|C0442027|C0085174|C0542559|G0000000|C0450371|G0000000|C0441587|C0085174
75,"76 ||| METHODS ||| 3.24 ||| The primary measures used to evaluate safety were the incidence of tachysystole, hypertonus, uterine hyperstimulation syndrome, and non-reassuring FHR.",N,primary measures evaluate safety incidence tachysystole hypertonus uterine hyperstimulation syndrome non-reassuring fhr,C0205225|C0079809|C0220825|C0036043|C0021149|C2985339|C0026826|C0042149|G0000000|C0039082|C1518422|G0000000
76,"99 ||| RESULTS ||| 4.10 ||| The groups were similar in mean maternal age, gestational age, initial Bishop score, and indications for labour induction, with postdates being the most common indication in both groups (66% in the oral misoprostol group and 76% vaginal misoprostol group).",P,maternal age gestational age initial bishop score indications labour induction postdates common indication 66% oral misoprostol 76% vaginal misoprostol,C2347083|C0001779|C0439671|C0001779|C0205265|C1551458|C0449820|C0392360|C0022864|C0205263|G0000000|C0205214|C0392360|C0450371|C0442027|C0085174|C0450371|C0042232|C0085174
77,133 ||| DISCUSSION ||| 5.20 ||| Flow diagram from randomization to,N,flow diagram randomization,C0806140|C0681494|C0034656
78,110 ||| RESULTS ||| 4.21 ||| Uterine hyperstimulation occurred in two women (1.8%) in the vaginal misoprostol group.,I,uterine hyperstimulation occurred women 1 8% vaginal misoprostol,C0042149|G0000000|C1709305|C0043210|G0000000|G0000000|C0042232|C0085174
79,125 ||| DISCUSSION ||| 5.12 ||| A limitation of our study is the lack of a placebo group and of blinding after randomization.,N,limitation study lack placebo blinding randomization,C0449295|C0557651|C0332268|C0032042|C0150108|C0034656
80,96 ||| RESULTS ||| 4.7 ||| Postpartum hemorrhage occurred in one patient (0.9%) in each group with cervical tear and vaginal lacerations.,N,postpartum hemorrhage occurred patient 0 9% cervical tear vaginal lacerations,C0086839|C0019080|C1709305|C0030705|G0000000|G0000000|C0027530|C0039409|C0042232|C0043246
81,"128 ||| DISCUSSION ||| 5.15 ||| Further, our study had a relatively small sample size to exclude the possibility of important differences (e.g., neonatal outcomes).",O,study sample size exclude possibility differences neonatal outcomes,C0557651|C0370003|C0456389|C0332196|C0332149|C1705241|C1552240|C1274040
82,106 ||| RESULTS ||| 4.17 ||| There was no perinatal mortality in either group.,N,perinatal mortality,C0178795|C0026565
83,79 ||| METHODS ||| 3.27 ||| Uterine tachysystole was defined as six or more uterine contractions in 10 minutes without concomitant abnormal FHR pattern.,N,uterine tachysystole defined uterine contractions 10 minutes concomitant abnormal fhr pattern,C0042149|C2985339|C1704788|C0042149|C1140999|C0450371|C0439232|C0521115|C0205161|G0000000|C0449774
84,72 ||| METHODS ||| 3.20 ||| The randomization list and envelopes were kept securely by the staff member.,N,randomization list envelopes securely staff,C0034656|C0745732|C1622204|G0000000|C0851286
85,107 ||| RESULTS ||| 4.18 ||| Mean induction-to-delivery interval in women who delivered vaginally was similar in oral and vaginal groups (21.22 hours in oral group versus 20.15 hours in vaginal group; P = 0.58) ( Table 2).,I,induction-to-delivery interval women delivered vaginally oral vaginal 21 22 hours oral versus 20 15 hours vaginal = 0 58 table 2,C0205263|C1272706|C0043210|C1705822|G0000000|C0442027|C0042232|C0450371|C0450371|C0439227|C0442027|G0000000|C0450371|C0450371|C0439227|C0042232|G0000000|G0000000|C0450371|C0039224|G0000000
86,1 |||  ||| 0.1 ||| Objectives: To assess and compare the efficacy and safety of 50 µg oral misoprostol and 25 µg intravaginal misoprostol for induction of labour at term.,P,objectives assess compare efficacy safety 50 oral misoprostol 25 intravaginal misoprostol induction labour term,C0018017|C1516048|C1707455|C1280519|C0036043|C0450371|C0442027|C0085174|C0450371|C0442122|C0085174|C0205263|C0022864|C0233324
87,40 ||| INTRODUCTION ||| 1.3 ||| Prostaglandin E 2 has been the agent of choice for pre-induction cervical ripening for several decades and is one of the pharmacologic agents approved by the United States Food and Drug Administration for this indication.,I,prostaglandin 2 agent choice pre-induction cervical ripening decades pharmacologic agents approved united food drug administration indication,C0033554|G0000000|C0450442|C0008300|C0332152|C0027530|C1160534|C2981279|C0031330|C0450442|C0205540|C0166872|C0016452|C0013227|C0001554|C0392360
88,45 ||| INTRODUCTION ||| 1.8 ||| Seyfettin et al.,N,seyfettin al,G0000000|C0202311
89,91 ||| RESULTS ||| 4.2 ||| Eight of the 228 women (3.5%) were excluded from the analysis.,P,228 women 3 5% excluded analysis,C1442061|C0043210|G0000000|G0000000|C1554077|C0002778
90,140 ||| ACKNOWLEDGEMENTS ||| 6.3 ||| This may have been because of the equivalent doses of misoprostol used for oral and vaginal administration in this study.,I,equivalent doses misoprostol oral vaginal administration study,C0205163|C0178602|C0085174|C0442027|C0042232|C0001554|C0557651
91,25 |||  ||| 0.25 ||| Résumé,N,rsum,G0000000
92,130 ||| DISCUSSION ||| 5.17 ||| The acceptability to women of the different routes of administration should also be evaluated.,I,acceptability women routes administration evaluated,C0814633|C0043210|C0449444|C0001554|C0220825
93,97 ||| RESULTS ||| 4.8 ||| There was no case of uterine rupture in either group.,N,uterine rupture,C0042149|C1881712
94,119 ||| DISCUSSION ||| 5.6 ||| Women with failed inductions were offered alternative methods of labour induction.,I,women failed inductions offered alternative methods labour induction,C0043210|C0231175|C0857127|C1444648|C1523987|C0025663|C0022864|C0205263
95,121 ||| DISCUSSION ||| 5.8 ||| This was a result of the greater bioavailability of vaginal misoprostol.,N,result bioavailability vaginal misoprostol,C1274040|C0005508|C0042232|C0085174
96,98 ||| RESULTS ||| 4.9 ||| The demographic characteristics and indications for induction of labour are shown in Table 1.,P,demographic characteristics indications induction labour table 1,C0011298|C1521970|C0392360|C0205263|C0022864|C0039224|G0000000
97,126 ||| DISCUSSION ||| 5.13 ||| The women and the clinicians involved in the study were aware of the allocated treatment.,I,women clinicians involved study aware allocated treatment,C0043210|C0871685|C1314939|C0557651|C0004448|G0000000|C0039798
98,124 ||| DISCUSSION ||| 5.11 ||| We hope that these findings will help provide direction for others in induction of labour using misoprostol in women at term.,O,hope findings provide direction induction labour misoprostol women term,C0392347|C2607943|C1999230|C0449738|C0205263|C0022864|C0085174|C0043210|C0233324
99,78 ||| METHODS ||| 3.26 ||| Adequate uterine contractions in this study were defined as occurring every two to three minutes and lasting 60 to 90 seconds.,O,adequate uterine contractions study defined occurring minutes lasting 60 90,C0205410|C0042149|C1140999|C0557651|C1704788|C1709305|C0439232|C1517741|C0450371|C0450371
100,28 |||  ||| 0.28 ||| Mean induction-to-delivery interval was similar in both groups (21 .22 hours in the oral group vs .,N,induction-to-delivery interval 21 22 hours oral,C0205263|C1272706|C0450371|C0450371|C0439227|C0442027
101,39 ||| INTRODUCTION ||| 1.2 ||| There is also a risk of ascending infection because of repeated vaginal examinations.,N,risk ascending infection repeated vaginal examinations,C0035647|C0205385|C0009450|C0205341|C0042232|C0031809
102,"17 |||  ||| 0.17 ||| L'intervalle déclenchement-accouchement moyen était semblable dans les deux groupes (21,22 heures au sein du groupe « oral » vs 20,15 heures au sein du groupe « vaginal »; P = 0,58).",N,lintervalle dclenchement-accouchement moyen tait semblable dans les deux groupes 21 22 heures au sein du groupe oral 20 15 heures au sein du groupe vaginal = 0 58,G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|C0227192|G0000000|G0000000|C0450371|C0450371|G0000000|C0004348|G0000000|C0011535|G0000000|C0442027|C0450371|C0450371|G0000000|C0004348|G0000000|C0011535|G0000000|C0042232|G0000000|G0000000|C0450371
103,135 ||| DISCUSSION ||| 5.22 ||| Maternal demographic characteristics and indications for induction of labour,P,maternal demographic characteristics indications induction labour,C2347083|C0011298|C1521970|C0392360|C0205263|C0022864
104,"112 ||| RESULTS ||| 4.23 ||| Non-reassuring FHR patterns necessitated urgent delivery in 14 women (12.7%) in the oral misoprostol group and 13 women (11.8%) in the vaginal misoprostol group (RR 1.04, 95% CI 0.71 to 1.54; P = 0.84).",I,non-reassuring fhr patterns necessitated urgent delivery 14 women 12 7% oral misoprostol 13 women 11 8% vaginal misoprostol rr 1 04 95% ci 0 71 1 54 = 0 84,C1518422|G0000000|C0449774|G0000000|C0439609|C0011209|C0450371|C0043210|C0450371|G0000000|C0442027|C0085174|C0450371|C0043210|C0450371|G0000000|C0042232|C0085174|G0000000|G0000000|C0450371|C0450371|C0008107|G0000000|C0450371|G0000000|C0450371|G0000000|G0000000|C0450371
105,22 |||  ||| 0.22 ||| Women either took 50 µg misoprostol orally (two 25 µg tablets) or had one 25 µg tablet of misoprostol inserted in the posterior vaginal fornix .,I,women 50 misoprostol orally 25 tablets 25 tablet misoprostol inserted posterior vaginal fornix,C0043210|C0450371|C0085174|C0442027|C0450371|C0039225|C0450371|C0039225|C0085174|C0441587|C0205095|C0042232|C0152334
106,102 ||| RESULTS ||| 4.13 ||| Neonatal outcomes are shown in Table 3.,N,neonatal outcomes table 3,C1552240|C1274040|C0039224|G0000000
107,50 ||| INTRODUCTION ||| 1.13 ||| Most clinical trials,N,clinical trials,C0205210|C0008976
108,"81 ||| METHODS ||| 3.29 ||| Nonreassuring FHR patterns in this study were defined as late deceleration, severe variable deceleration, prolonged deceleration, tachycardia, or reduced FHR variability requiring intervention either by tocolysis or delivery.",P,nonreassuring fhr patterns study defined late deceleration severe variable deceleration prolonged deceleration tachycardia reduced fhr variability requiring intervention tocolysis delivery,G0000000|G0000000|C0449774|C0557651|C1704788|C0205087|C0011100|C0205082|C0439828|C0011100|C0439590|C0011100|C0039231|C0392756|G0000000|C2827666|G0000000|C0886296|C0040348|C0011209
109,"58 ||| METHODS ||| 3.6 ||| Women met the inclusion criteria if they were nulliparous or multiparous with a singleton pregnancy between 37 and 42 weeks' gestation, with obstetric or medical indications for induction of labour and an unfavourable cervix (initial Bishop score of ≤ 6), a vertex presentation, a reactive FHR pattern, and absence of uterine contractions.",P,women met inclusion criteria nulliparous multiparous singleton pregnancy 37 42 weeks gestation obstetric medical indications induction labour unfavourable cervix initial bishop score 6 vertex presentation reactive fhr pattern absence uterine contractions,C0043210|C0268621|C0007637|C0243161|C0425979|C0026751|C0481462|C0032961|C0450371|C0450371|C0439230|C0032961|C0205484|C0199168|C0392360|C0205263|C0022864|C3640815|C0007874|C0205265|C1551458|C0449820|G0000000|C0230003|C0449450|C0205332|G0000000|C0449774|C0332197|C0042149|C1140999
110,9 |||  ||| 0.9 ||| Mean induction-to-delivery interval was similar in both groups (21 .22 hours in the oral group vs. 20 .15 hours in the vaginal group; P = 0 .58).,I,induction-to-delivery interval 21 22 hours oral 20 15 hours vaginal = 0 58,C0205263|C1272706|C0450371|C0450371|C0439227|C0442027|C0450371|C0450371|C0439227|C0042232|G0000000|G0000000|C0450371
111,"69 ||| METHODS ||| 3.17 ||| Women fulfilling the eligibility criteria were randomized into two groups: in one misoprostol was administered orally, and in the other vaginally.",P,women fulfilling eligibility criteria randomized misoprostol administered orally vaginally,C0043210|C1550543|C0013893|C0243161|C0034656|C0085174|C1521801|C0442027|G0000000
112,26 |||  ||| 0.26 ||| Objectifs : Évaluer et comparer l'efficacité et l'innocuité de 50 µg de misoprostol par voie orale et de 25 µg de misoprostol par voie intravaginale pour le déclenchement du travail à terme .,N,objectifs valuer comparer lefficacit linnocuit de 50 de misoprostol par voie orale de 25 de misoprostol par voie intravaginale pour le dclenchement du travail terme,G0000000|C0401806|G0000000|G0000000|G0000000|C0011198|C0450371|C0011198|C0085174|C1417826|G0000000|C2333746|C0011198|C0450371|C0011198|C0085174|C1417826|G0000000|G0000000|G0000000|C0023190|G0000000|C0011535|G0000000|G0000000
113,13 |||  ||| 0.13 ||| Ces femmes ont été affectées au hasard à un groupe devant prendre 50 µg de misoprostol par voie orale (deux comprimés de 25 µg) ou à un groupe devant se faire insérer un comprimé de 25 µg de misoprostol dans le cul-de-sac postérieur du vagin.,N,ces femmes ont affectes au hasard groupe devant prendre 50 de misoprostol par voie orale deux comprims de 25 ou groupe devant se faire insrer comprim de 25 de misoprostol dans le cul-de-sac postrieur du vagin,C0265493|G0000000|G0000000|G0000000|C0004348|G0000000|G0000000|G0000000|G0000000|C0450371|C0011198|C0085174|C1417826|G0000000|C2333746|G0000000|G0000000|C0011198|C0450371|C0229118|G0000000|G0000000|C0036919|G0000000|G0000000|G0000000|C0011198|C0450371|C0011198|C0085174|G0000000|C0023190|C0013075|G0000000|C0011535|C1522570
114,68 ||| METHODS ||| 3.16 ||| Women who refused further induction and requested operative delivery were delivered by CS.,I,women refused induction requested operative delivery delivered cs,C0043210|C1548564|C0205263|C1272683|C1882154|C0011209|C1705822|C0010182
115,"11 |||  ||| 0.11 ||| Uterine hyperstimulation occurred in two women who received misoprostol vaginally, but not in any of the women in the oral misoprostol group.",I,uterine hyperstimulation occurred women received misoprostol vaginally women oral misoprostol,C0042149|G0000000|C1709305|C0043210|C1514756|C0085174|G0000000|C0043210|C0442027|C0085174
116,49 ||| INTRODUCTION ||| 1.12 ||| There have been few randomized trials conducted comparing 50 µg oral misoprostol with 25 µg intravaginal misoprostol for labour induction.,I,randomized trials conducted comparing 50 oral misoprostol 25 intravaginal misoprostol labour induction,C0034656|C0008976|C0004927|C1707455|C0450371|C0442027|C0085174|C0450371|C0442122|C0085174|C0022864|C0205263
117,"77 ||| METHODS ||| 3.25 ||| The secondary outcome measures used to evaluate the efficacy or safety of treatment included the number of doses of misoprostol needed to effect delivery, requirement for oxytocin, the incidence of failed induction, the rate of CS, maternal adverse effects (nausea/vomiting, diarrhea, fever, postpartum hemorrhage, uterine rupture), and neonatal outcomes comprising low Apgar score (< 7 at 5 minutes), incidence of meconium-stained amniotic fluid, need for NICU admission, neonatal seizure within 48 hours of birth, and perinatal mortality rate.",N,secondary outcome measures evaluate efficacy safety treatment included doses misoprostol delivery requirement oxytocin incidence failed induction rate cs maternal adverse effects nausea/vomiting diarrhea fever postpartum hemorrhage uterine rupture neonatal outcomes comprising low apgar score < 7 5 minutes incidence meconium-stained amniotic fluid nicu admission neonatal seizure 48 hours birth perinatal mortality rate,C0027627|C1274040|C0079809|C0220825|C1280519|C0036043|C0039798|C0332257|C0178602|C0085174|C0011209|C1514873|C0030095|C0021149|C0231175|C0205263|C0871208|C0010182|C2347083|G0000000|C1280500|C0027498|C0011991|C0015967|C0086839|C0019080|C0042149|C1881712|C1552240|C1274040|C2700400|C0205251|C0741195|C0449820|G0000000|G0000000|G0000000|C0439232|C0021149|C1112318|C0002630|C0005889|C0021709|C0184666|C1552240|C0036572|C0450371|C0439227|C0005615|C0178795|C0026565|C0871208
118,4 |||  ||| 0.4 ||| Women either took 50 µg misoprostol orally (two 25 µg tablets) or had one 25 µg tablet of misoprostol inserted in the posterior vaginal fornix.,I,women 50 misoprostol orally 25 tablets 25 tablet misoprostol inserted posterior vaginal fornix,C0043210|C0450371|C0085174|C0442027|C0450371|C0039225|C0450371|C0039225|C0085174|C0441587|C0205095|C0042232|C0152334
119,89 ||| METHODS ||| 3.37 ||| OBSTETRICS,N,obstetrics,C0028773
120,143 ||| ACKNOWLEDGEMENTS ||| 6.6 ||| Uterine tachysystole occurred in two women (1.8%) in the oral misoprostol group and six women (5.5%) in the vaginal misoprostol group.,I,uterine tachysystole occurred women 1 8% oral misoprostol women 5 5% vaginal misoprostol,C0042149|C2985339|C1709305|C0043210|G0000000|G0000000|C0442027|C0085174|C0043210|G0000000|G0000000|C0042232|C0085174
121,"63 ||| METHODS ||| 3.11 ||| If labour was established or the Bishop's score was 7 or more, the woman was transferred to the labour ward, and artificial rupture of membranes was performed at the discretion of the attending clinician.",I,labour established bishops score 7 woman transferred labour ward artificial rupture membranes performed discretion attending clinician,C0022864|C0443211|C0649610|C0449820|G0000000|C0043210|C0348011|C0022864|C1305702|C2004457|C1881712|C0025255|C0884358|G0000000|C1547429|C0871685
122,95 ||| RESULTS ||| 4.6 ||| The incidence of adverse effects of treatment also was similar in each group (Table 2).,N,incidence adverse effects treatment table 2,C0021149|G0000000|C1280500|C0039798|C0039224|G0000000
123,46 ||| INTRODUCTION ||| 1.9 ||| These were all multiple dose trials.,N,multiple dose trials,C0439064|C0178602|C0008976
124,56 ||| METHODS ||| 3.4 ||| Written informed consent was obtained from the women who participated in the study.,N,written informed consent women participated study,C0043266|C1522154|C1511481|C0043210|G0000000|C0557651
125,"27 |||  ||| 0.27 ||| Results: Of the 228 women, eight (3 .5%) were excluded from the analysis as they withdrew their consent after randomization .",P,228 women 3 5% excluded analysis withdrew consent randomization,C1442061|C0043210|G0000000|G0000000|C1554077|C0002778|C2349954|C1511481|C0034656
126,92 ||| RESULTS ||| 4.3 ||| Three women assigned to the oral misoprostol group and five women assigned to the vaginal misoprostol group withdrew their consent after randomization.,N,women assigned oral misoprostol women assigned vaginal misoprostol withdrew consent randomization,C0043210|C1516050|C0442027|C0085174|C0043210|C1516050|C0042232|C0085174|C2349954|C1511481|C0034656
127,44 ||| INTRODUCTION ||| 1.7 ||| Oral misoprostol in a dose of 50 µg was found by Windrim et al.,N,oral misoprostol dose 50 windrim al,C0442027|C0085174|C0178602|C0450371|G0000000|C0202311
128,"23 |||  ||| 0.23 ||| In each group, misoprostol administration was repeated every four hours in the same dose until regular uterine contractions were established or to a maximum of five doses .",I,misoprostol administration repeated hours dose regular uterine contractions established maximum doses,C0085174|C0001554|C0205341|C0439227|C0178602|C0205272|C0042149|C1140999|C0443211|C0806909|C0178602
129,"54 ||| METHODS ||| 3.2 ||| The Central Referral Hospital, a teaching hospital of the Sikkim Manipal Institute of Medical Sciences, is one of the major hospitals in the Eastern Himalayan region, catering to the population of Gangtok and remote areas of Sikkim province, India.",N,central referral hospital teaching hospital sikkim manipal institute medical sciences major hospitals eastern himalayan region catering population gangtok remote sikkim province india,C0205099|C0034927|C0019994|C0039401|C0019994|C0037091|G0000000|C0021622|C0199168|C0036397|C0205082|C0019994|C1707877|G0000000|C0017446|G0000000|C0032659|G0000000|C0205157|C0037091|C1514578|C0021201
130,"29 |||  ||| 0.29 ||| There was no significant difference between the groups with respect to the number of women who delivered within 24 hours or who required oxytocin augmentation of labour, the mode of delivery, and neonatal outcomes (P > 0 .05) .",N,difference respect women delivered 24 hours required oxytocin augmentation labour mode delivery neonatal outcomes 0 05,C1705241|C0679133|C0043210|C1705822|C0450371|C0439227|C1514873|C0030095|C1293122|C0022864|C1513371|C0011209|C1552240|C1274040|G0000000|C0450371
131,"123 ||| DISCUSSION ||| 5.10 ||| The most important finding of this study was that the mean induction-to-vaginal delivery interval and the number of women who delivered within 24 hours was similar in the oral and vaginal misoprostol groups, with no difference in CS rates and neonatal outcomes.",O,finding study induction-to-vaginal delivery interval women delivered 24 hours oral vaginal misoprostol difference cs rates neonatal outcomes,C0037088|C0557651|C0205263|C0011209|C1272706|C0043210|C1705822|C0450371|C0439227|C0442027|C0042232|C0085174|C1705241|C0010182|C0871208|C1552240|C1274040
132,62 ||| METHODS ||| 3.10 ||| FHR was also monitored every 30 minutes by intermittent fetal auscultation.,I,fhr monitored 30 minutes intermittent fetal auscultation,G0000000|C0030695|C0450371|C0439232|C0205267|C0015965|C0004339
133,"85 ||| METHODS ||| 3.33 ||| Statistical analysis included calculation of relative risk with 95% confidence intervals for discrete data, and mean differences with 95% confidence intervals for continuous data, using InStat GraphPad v. 3 software (GraphPad Software Inc., La Jolla, CA).",I,statistical analysis included calculation relative risk 95% confidence intervals discrete data differences 95% confidence intervals continuous data instat graphpad 3 software graphpad software la jolla,C0038215|C0002778|C0332257|C1441506|C0080103|C0035647|C0450371|C0237529|C1272706|C0443299|C1511726|C1705241|C0450371|C0237529|C1272706|C0549178|C1511726|G0000000|G0000000|G0000000|C0037585|G0000000|C0037585|C0023031|C1493068
134,94 ||| RESULTS ||| 4.5 ||| Details of the randomization are shown in Figure 1. outcomes in the two groups are shown schematically in Figure 2.,N,details randomization figure 1 outcomes schematically figure 2,C1522508|C0034656|G0000000|G0000000|C1274040|G0000000|G0000000|G0000000
135,90 ||| RESULTS ||| 4.1 ||| Two hundred twenty-eight pregnant women with obstetric or medical indications for induction of labour were randomized during the study period before the recruitment was stopped.,P,twenty-eight pregnant women obstetric medical indications induction labour randomized study period recruitment stopped,C0724000|C0549206|C0043210|C0205484|C0199168|C0392360|C0205263|C0022864|C0034656|C0557651|C0439531|C2949735|C1272691
136,84 ||| METHODS ||| 3.32 ||| The data were analyzed by intention-to-treat.,N,data analyzed intention-to-treat,C1511726|C0936012|C0162425
137,"70 ||| METHODS ||| 3.18 ||| A staff member not involved with the trial generated allocation envelopes for each group, using the random number table, which were then sealed in consecutively numbered opaque envelopes.",I,staff involved trial generated allocation envelopes random table sealed consecutively numbered opaque envelopes,C0851286|C1314939|C0008976|C3146294|C1706778|C1622204|C0034656|C0039224|C0036492|G0000000|C0449788|C0029053|C1622204
138,15 |||  ||| 0.15 ||| Le délai jusqu'à l'accouchement et les données quant aux issues ont été comparés chez ces groupes.,N,le dlai jusqu laccouchement les donnes quant aux issues ont compars chez ces groupes,C0023190|G0000000|G0000000|G0000000|C0227192|G0000000|G0000000|G0000000|C0033213|G0000000|G0000000|G0000000|C0265493|G0000000
139,"74 ||| METHODS ||| 3.22 ||| Women in the oral misoprostol group received 50 µg misoprostol (2 tablets of 25 µg) orally with a sip of water, and women in the vaginal misoprostol group had one 25 µg misoprostol tablet inserted by a trained staff physician in the posterior vaginal fornix without use of lubricant.",I,women oral misoprostol received 50 misoprostol 2 tablets 25 orally sip water women vaginal misoprostol 25 misoprostol tablet inserted trained staff physician posterior vaginal fornix lubricant,C0043210|C0442027|C0085174|C1514756|C0450371|C0085174|G0000000|C0039225|C0450371|C0442027|C1823796|C0043047|C0043210|C0042232|C0085174|C0450371|C0085174|C0039225|C0441587|C0336809|C0851286|C0031831|C0205095|C0042232|C0152334|C0282222
140,"113 ||| RESULTS ||| 4.24 ||| Of these, 10 of 14 in the oral misoprostol and seven of 13 in the vaginal misoprostol group (including two with hyperstimulation syndrome) underwent CS.",N,10 14 oral misoprostol 13 vaginal misoprostol including hyperstimulation syndrome underwent cs,C0450371|C0450371|C0442027|C0085174|C0450371|C0042232|C0085174|C0332257|G0000000|C0039082|G0000000|C0010182
141,114 ||| DISCUSSION ||| 5.1 ||| Multiple trials have shown that misoprostol is an effective agent for cervical ripening and labour induction.,O,multiple trials misoprostol effective agent cervical ripening labour induction,C0439064|C0008976|C0085174|C1280519|C0450442|C0027530|C1160534|C0022864|C0205263
142,"3 |||  ||| 0.3 ||| Methods: This non-blinded, randomized clinical trial included 228 pregnant women at term with obstetric or medical indications for induction of labour.",P,methods non-blinded randomized clinical trial included 228 pregnant women term obstetric medical indications induction labour,C0025663|C1518422|C0034656|C0205210|C0008976|C0332257|C1442061|C0549206|C0043210|C0233324|C0205484|C0199168|C0392360|C0205263|C0022864
143,93 ||| RESULTS ||| 4.4 ||| The final analysis was performed on data from 220 women.,N,final analysis performed data 220 women,C0205088|C0002778|C0884358|C1511726|C1442061|C0043210
144,137 ||| DISCUSSION ||| 5.24 ||| Comparison of neonatal outcomes,N,comparison neonatal outcomes,C1707455|C1552240|C1274040
